ENLV Enlivex Limited
Enlivex Limited (ENLV) is expected to report earnings on May 29, 2026, before the market open. The consensus earnings estimate is a loss of $0.31 per share.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Enlivex Limited
Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve hyper-expression of cytokines (Cytokine Release Syndrome) and for which there are no approved treatments (unmet medical needs), as well as solid tumors immune-checkpoint rebalancing.
Sector
Healthcare
Industry
Drug Manufacturers/Other